Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.39 |
| ▸ | GABRE | P78334 | 1/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.39 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4528112 | 0.84 | HSD17B10 (0.37) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6802200 | 0.79 | FBP1 (0.51) | HPGDALDH1A1FBP1GAAKMT2A | |
| SCHEMBL781841 | 0.77 | FBP1 (0.56) | CYP1A2HPGDALDH1A1FBP1GAA | |
| SCHEMBL286999 | 0.76 | HSD17B10 (0.47) | CYP1A2HPGDTSHRALDH1A1GAA | |
| SCHEMBL2180444 | 0.75 | GABRP (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Hydrochloric Acid SCHEMBL10496189 | 0.74 | HSD17B10 (0.46) | CYP1A2HPGDTSHRALDH1A1GAA | |
| SCHEMBL3822759 | 0.74 | ALDH1A1 (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL11163237 | 0.73 | CYP1A2 (0.37) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL11173035 | 0.73 | ALDH1A1 (0.45) | CYP1A2HPGDTSHRALDH1A1GAA | |
| SCHEMBL11166176 | 0.73 | CYP1A2 (0.37) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-106478497-B | Arylamine derivatives as TTX-S blockers | 拉夸里亚创药株式会社 | 2020-05-08 | — | — | CN | disclosed |
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-9302991-B2 | Arylamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| EP-2630122-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
| EP-1954696-B1 | 2-PHENOXY-N-(1,3,4-THIADIZOL-2-YL)PYRIDIN-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-23 | — | — | EP | disclosed |
| CN-101481359-A | Cyclic protein tyrosine kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-07-15 | — | — | CN | disclosed |
| CN-1764454-A | Cyclic inhibitors of protein tyrosine kinases | BRISTOL MYERS SQUIBB CO (US) | 2006-04-26 | — | — | CN | disclosed |
| CN-1348370-A | Cyclic protein tyrosine kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2002-05-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN2B, SCN1B, SCN2A | GABRP 342/4885GABRD 285/4885GABRA1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.